Table 4. Logistic regression analysis showing the effect of various systemic variables.
| Variable | B | SE | P-value | Odds ratio (OR) |
95% C.I. for OR |
|
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age | −0.05 | 0.06 | 0.39 | 0.95 | 0.85 | 1.07 |
| Male | 0.78 | 0.86 | 0.36 | 2.18 | 0.41 | 11.69 |
| Type I diabetes | 1.65 | 2.09 | 0.43 | 5.22 | 0.09 | 316.65 |
| Duration of diabetes | −0.37 | 0.15 | 0.01 | 0.69 | 0.52 | 0.92 |
| HbA1c | 0.01 | 0.24 | 0.98 | 1.01 | 0.63 | 1.60 |
| Hypertension | −2.410 | 1.32 | 0.07 | 0.09 | 0.01 | 1.20 |
| Systolic BP | 0.06 | 0.03 | 0.03 | 1.06 | 1.01 | 1.12 |
| Diastolic BP | −0.10 | 0.06 | 0.07 | 0.90 | 0.81 | 1.01 |
| Co-existent ischaemic heart disease (IHD) | −3.06 | 1.19 | 0.01 | 0.05 | 0.010 | 0.48 |
| Serum total cholesterol | 2.00 | 1.18 | 0.07 | 7.39 | 0.84 | 64.79 |
| Co-existent cerebrovascular accident (CVA) | −0.31 | 1.61 | 0.85 | 0.74 | 0.03 | 17.36 |
| Interval (months) for the clinician to make the decision to operate | −0.51 | 0.22 | 0.02 | 0.60 | 0.39 | 0.92 |
| Intravitreal bevacizumab | −0.88 | 0.90 | 0.33 | 0.41 | 0.07 | 2.43 |
| Appointments not attended by the patient | −0.54 | 0.19 | 0.01 | 0.58 | 0.40 | 0.86 |
Abbreviation: B, unstandardized coefficient.